The promising role of bioactive congeners present in Cassytha filiformis in Alzheimer's disease: An explicative review

Abstract

The most prevalent form of dementia in older persons is Alzheimer's disease (AD), a chronic neurodegenerative disorder that results in a progressive loss of cognitive function and deterioration in reasoning abilities. Given the well-known multifactorial nature of AD, numerous pharmaceutical targets can be investigated. The widely recognized regulator glycogen synthase kinase-3 (GSK-3) is involved in the development and subsequent progression of the pathophysiology of AD and regulates several crucial targets related to neuronal degeneration. GSK-3 inhibition has neuroprotective benefits, lowers -amyloid formation, and lowers tau hyperphosphorylation, all of which are linked to AD. Strong GSK-3 blockers with a wide range of structural variations have been discovered recently. There are negative impacts of these artificial compounds. Natural products are one of the most significant and conservative sources of pharmaceuticals for treating neurological conditions.A medicinal herb called Cassytha filiformis L. has historically been used to cure various illnessesas traditional Chinese medicine. In addition to being utilized medicinally in China, Indochina, Madagascar, and South Africa, this plant is more widely distributed throughout India. The plant's extracts contain aporphine alkaloid, cassyformine, filiformine, cathaformine, and other unique chemicals. Research on C. filiformis has revealed that it contains several chemical compounds that are biologically active and can potentially treat human health issues. To uncover the Cassytha filiformis plant's medicinal characteristics and its use in the pharmaceutical sectors, we have examined the plant's numerous aspects and collated its pharmacological applications, notably anti-Alzheimer's activity.

Keywords

• Cassytha filiformis
• Cassyfiline
• In silico
• Alzheimer's disease
• Natural compounds